DEFA14A: NeuroOne Medical Technologies Revises Equity Incentive Plan Ahead of 2025 Annual Meeting

NeuroOne Medical Technologies amends its 2025 Equity Incentive Plan to remove the evergreen feature following stockholder feedback, seeking approval at the upcoming annual meeting.

Summary

• NeuroOne Medical Technologies is supplementing its proxy statement for the 2025 Annual Meeting of Stockholders to be held on February 14, 2025.
• The supplement addresses Proposal No. 4, which concerns the approval of the NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan.
• Following discussions with stockholders, the Board of Directors adopted a revised 2025 Plan on February 4, 2025, contingent upon stockholder approval.
• The key revision is the elimination of the evergreen feature, which provided for automatic annual increases in the number of shares available under the plan.
• The aggregate number of shares of common stock that may be issued under the 2025 Plan will not exceed the sum of 3,000,000 and any shares subject to outstanding stock awards under the 2017 Plan that are forfeited or otherwise returned to the share reserve.
• At December 31, 2024, equity awards covering an aggregate of 3,906,056 shares were outstanding under the 2017 Plan and the Inducement Plan.
• The company believes that equity awards are a vital part of its overall compensation program and are crucial for attracting, recruiting, and retaining employees and consultants.
• The Board recommends a vote for approval of Proposal No. 4.

Sentiment

Score: 7

Explanation: The document reflects a proactive approach to compensation and responsiveness to shareholder concerns, which is generally positive. However, the need for equity compensation suggests potential cash constraints, slightly lowering the sentiment score.

Positives

• The company is responsive to stockholder feedback by removing the evergreen provision from the equity incentive plan.
• The company believes equity awards are vital for attracting and retaining talent.
• The company is committed to using the shares available under the 2025 Plan prudently to advance the company's interests.
• The company's compensation philosophy reflects broad-based eligibility for equity incentive awards, and the company grants awards to substantially all of its employees.

Negatives

• Equity awards dilute existing stockholders.
• The company has relied upon and anticipates continuing to rely upon the equity incentive program to a disproportionate degree in lieu of cash compensation to its executive officers.

Risks

• If the plan is not approved, the company may face challenges in attracting and retaining key personnel.
• The life sciences market is highly competitive, and the company competes for talent with companies that offer aggressive equity compensation.
• The company recognizes that equity awards dilute existing stockholders, and, therefore, the company must responsibly manage its use of equity compensation.

Future Outlook

The company intends to continue relying on equity incentives to attract and retain employees and consultants, positioning its pay at a competitive opportunity level while reducing emphasis on cash compensation.

Management Comments

• Our Board believes that it is in the best interest of us and our stockholders for the Company to be in a position to offer equity awards to executive officers, key employees, outside directors, consultants and advisors in accordance with the terms of the 2025 Plan.
• Our Board believes that the structure of these agreements benefits stockholders by providing additional incentive to the executives regarding value creation.

Industry Context

In the competitive life sciences market, equity compensation is a crucial tool for attracting and retaining talent, with many competitors offering aggressive equity packages, including evergreen plans.

Comparison to Industry Standards

• Many of NeuroOne's competitors have evergreen plans that allow automatic replenishment of the equity share pool on an annual basis.
• NeuroOne is requesting stockholder approval for a larger share pool together with an evergreen provision to provide for annual increases in the share pool that will accommodate future equity awards needed to achieve recruiting and retention goals.

Corporate Governance

Stakeholder Impact

• Stockholders: Potential dilution from equity awards, but also potential benefits from attracting and retaining talent.
• Employees and Consultants: Opportunity to receive equity compensation.
• Executive Officers: Additional incentive for value creation.

Next Steps

• Stockholder vote on Proposal No. 4 at the Annual Meeting on February 14, 2025.
• Filing of a registration statement on Form S-8 with the SEC if the 2025 Plan is approved.

Key Dates

Keywords

Equity Incentive Plan, Stockholder Approval, Share Pool, Evergreen Provision, Equity Awards, Compensation, NeuroOne